Grufity logoGrufity logo
StocksFundsSearch FilingsAPI

Shockwave Medical Inc Stock Research

SWAV

190.04USD-6.27(-3.19%)Delayedas of 03 Oct 2023, 03:36 pm
Watchlist

Market Summary

USD190.04-6.27
Delayedas of 03 Oct 2023, 03:36 pm
-3.19%

SWAV Alerts

  • 3 major insider sales recently.
  • Big jump in Revenue (Y/Y)

SWAV Stock Price

SWAV RSI Chart

SWAV Valuation

Market Cap

7.2B

Price/Earnings (Trailing)

29.51

Price/Sales (Trailing)

11.67

EV/EBITDA

43.2

Price/Free Cashflow

56.92

SWAV Price/Sales (Trailing)

SWAV Profitability

EBT Margin

26.36%

Return on Equity

42.16%

Return on Assets

30.72%

Free Cashflow Yield

1.76%

SWAV Fundamentals

SWAV Revenue

Revenue (TTM)

616.6M

Revenue Y/Y

49.21%

Revenue Q/Q

11.86%

SWAV Earnings

Earnings (TTM)

243.9M

Earnings Y/Y

12.91%

Earnings Q/Q

-26.23%

Price Action

52 Week Range

172.50320.54
(Low)(High)

Last 7 days

1.0%

Last 30 days

-11.7%

Last 90 days

-29.6%

Trailing 12 Months

-29.4%

SWAV Financial Health

Current Ratio

4.16

Debt/Equity

0.03

Debt/Cashflow

7.93

SWAV Investor Care

Shares Dilution (1Y)

2.34%

Diluted EPS (TTM)

6.42

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales

Latest Insider Trading transactions for SWAV

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-09-26
Zacharias Isaac
sold
-768,480
192
-4,000
president, cco
2023-09-20
WATKINS FRANK T
acquired
10,248
3.416
3,000
-
2023-09-20
WATKINS FRANK T
sold
-627,690
209
-3,000
-
2023-09-15
Godshall Douglas Evan
acquired
34,160
3.416
10,000
president & ceo
2023-09-15
Godshall Douglas Evan
sold
-2,128,610
212
-10,000
president & ceo
2023-09-11
Zacharias Isaac
sold (taxes)
-123,949
229
-541
president, cco
2023-09-08
Papiernik Antoine
sold
-
-
-21,926
-
2023-09-05
Phung Trinh
sold (taxes)
-5,269
219
-24.00
vp, finance
2023-08-29
Phung Trinh
acquired
17,080
3.416
5,000
vp, finance
2023-08-25
Zacharias Isaac
sold
-819,920
204
-4,000
president, cco

1–10 of 50

Which funds bought or sold SWAV recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-09-26
BROOKFIELD Corp /ON/
reduced
-68.69
-1,408,670
987,519
-%
2023-09-20
BARCLAYS PLC
added
11.33
4,724,000
14,867,000
0.01%
2023-09-12
Farther Finance Advisors, LLC
added
25.00
4,477
11,416
-%
2023-08-29
EFG Asset Management (Americas) Corp.
reduced
-8.59
66,658
394,722
0.09%
2023-08-23
WOLVERINE TRADING, LLC
reduced
-17.18
51,872
551,872
-%
2023-08-22
VIRGINIA RETIREMENT SYSTEMS ET AL
added
9.9
978,068
3,168,050
0.03%
2023-08-22
COMERICA BANK
new
-
49,000
49,000
-%
2023-08-21
TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY
added
184
3,441,000
4,694,000
0.04%
2023-08-21
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
reduced
-1.58
2,882,400
12,639,100
0.02%
2023-08-21
BOKF, NA
reduced
-61.54
-1,392
1,427
-%

1–10 of 45

Latest Funds Activity

Are funds buying SWAV calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own SWAV
No. of Funds

Schedule 13G FIlings of Shockwave Medical

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2023
price t rowe associates inc /md/
2.8%
1,012,393
SC 13G/A
Feb 09, 2023
fmr llc
-
0
SC 13G/A
Jan 23, 2023
blackrock inc.
12.7%
4,572,659
SC 13G/A
Jan 10, 2023
vanguard group inc
10.22%
3,694,931
SC 13G/A
Jul 08, 2022
blackrock inc.
12.1%
4,313,553
SC 13G
Feb 14, 2022
price t rowe associates inc /md/
8.7%
3,077,252
SC 13G/A
Feb 14, 2022
gilder gagnon howe & co llc
3.9%
1,384,358
SC 13G/A
Feb 03, 2022
blackrock inc.
7.7%
2,716,533
SC 13G/A
Jan 10, 2022
fmr llc
-
0
SC 13G/A
Nov 09, 2021
jpmorgan chase & co
3.4%
1,209,265
SC 13G/A

Recent SEC filings of Shockwave Medical

View All Filings
Date Filed Form Type Document
Sep 27, 2023
4
Insider Trading
Sep 25, 2023
144
Notice of Insider Sale Intent
Sep 21, 2023
4
Insider Trading
Sep 20, 2023
144
Notice of Insider Sale Intent
Sep 19, 2023
4
Insider Trading
Sep 15, 2023
144
Notice of Insider Sale Intent
Sep 12, 2023
4
Insider Trading
Sep 12, 2023
4
Insider Trading
Sep 11, 2023
8-K
Current Report
Sep 06, 2023
4
Insider Trading

SWAV Fair Value

Loading...

Peers (Alternatives to Shockwave Medical)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
104.0B
19.5B
-3.73% 35.20%
38.38
5.34
10.36% 30.30%
103.6B
6.7B
-4.97% 57.37%
72.72
15.55
11.75% -0.66%
76.4B
13.4B
-1.51% 36.35%
83.74
5.7
8.69% 3.17%
71.3B
19.0B
-7.43% 16.56%
44.09
3.79
0.46% -5.24%
42.1B
5.7B
-9.43% -16.28%
30.27
7.43
5.64% -4.53%
MID-CAP
9.1B
937.8M
-9.65% 25.86%
313.94
9.75
16.30% 250.21%
7.2B
616.6M
-11.74% -29.40%
29.51
11.67
69.52% 343.68%
5.0B
1.1B
-8.56% -16.75%
23.67
4.54
12.63% 50.85%
2.8B
452.1M
-10.08% -26.48%
-28.35
6.22
24.99% 24.09%
1.4B
790.3M
-21.04% -54.04%
-6.37
1.81
3.21% -1604.53%
SMALL-CAP
1.5B
421.8M
-22.58% 43.94%
-9.18
3.63
44.49% -2.43%
945.1M
780.7M
-5.83% -7.35%
-26.25
1.21
4.68% -510.17%
839.3M
239.8M
0.70% 0.15%
-22.16
3.5
-4.74% -31.15%
589.9M
162.9M
-22.80% -66.22%
-11.16
3.62
42.67% 12.82%

Shockwave Medical News

The Motley Fool
3 Healthcare Stocks to Keep an Eye On.
The Motley Fool,
5 hours ago
Investing.com UK
Yahoo Finance

Returns for SWAV

Cumulative Returns on SWAV

37.8%


3-Year Cumulative Returns

Risks for SWAV

What is the probability of a big loss on SWAV?

98.3%


Probability that Shockwave Medical stock will be more than 20% underwater in next one year

74.7%


Probability that Shockwave Medical stock will be more than 30% underwater in next one year.

62.7%


Probability that Shockwave Medical stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does SWAV drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Shockwave Medical was unfortunately bought at previous high price.

Drawdowns

Financials for Shockwave Medical

Income Statement (Last 12 Months)
Income Statement (Last 12 Months)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Revenue10.7%616,587,000557,168,000489,733,000429,890,000363,715,000298,877,000237,146,000175,679,000130,114,00084,492,00067,789,00059,385,00051,128,00050,854,00042,927,00033,676,00025,943,00018,210,00012,263,0009,601,3337,202,000
Gross Profit10.7%535,652,000483,996,000424,737,000369,733,000310,483,000252,441,000195,708,000140,433,000100,540,00061,260,00046,798,00039,312,00031,931,00031,116,00025,768,00022,677,33320,152,00016,788,0005,013,000--
Operating Expenses------------107,133,33397,636,00087,538,667-71,313,33366,976,00065,424,000---
  S&GA Expenses9.0%196,268,000180,045,000161,995,000151,748,000138,059,000123,257,000111,288,00094,534,00079,760,00065,253,00051,672,00044,833,00039,406,00035,161,00030,620,00025,949,00022,558,00019,969,00017,536,00016,814,66715,620,000
  R&D Expenses17.5%107,700,00091,631,00081,679,00072,673,00066,231,00057,286,00050,544,00044,871,00039,027,00035,313,00036,926,00037,957,00038,434,00037,259,00032,853,00028,897,00026,062,00024,666,00022,698,00022,105,33322,092,000
EBITDA-100.0%-154,727,000127,614,00094,677,00061,257,00034,353,000-4,139,000-33,453,000-48,837,000-67,019,000-62,544,000-61,547,000-61,784,000-54,523,000-48,766,000-45,506,000-42,995,000----
EBITDA Margin-100.0%-0.280.260.220.170.11-0.02-0.19-0.38-0.79-0.92-1.04-1.21-1.07-1.14-1.35-1.66----
Interest Expenses22.5%2,699,0002,203,0001,900,0001,222,0001,071,0001,085,0001,100,0001,098,0001,247,0001,235,0001,200,0001,095,0001,032,000976,000944,000931,000838,000628,000401,000288,000116,000
Earnings Before Taxes4.5%153,516,000146,847,000120,828,00089,222,00056,127,00029,440,000-8,835,000-37,750,000-52,679,000-70,424,000-65,619,000-64,486,000-64,514,000-57,007,000-51,047,000-47,525,000-44,766,000-44,262,000-41,064,000-39,802,666-39,360,000
EBT Margin-100.0%-0.260.250.210.150.10-0.04-0.21-0.40-0.83-0.97-1.09-1.26-1.12-1.19-1.41-1.73----
Net Income1.4%243,901,000240,600,000215,996,00088,027,00054,972,00028,986,000-9,136,000-37,952,000-52,832,000-70,525,000-65,699,000-64,570,000-64,595,000-57,085,000-51,109,000-47,587,000-44,808,000-44,307,000-41,102,000-39,838,666-39,402,000
Net Income Margin-100.0%-0.430.440.200.150.10-0.04-0.22-0.41-0.83-0.97-1.09-1.26-1.12-1.19-1.41-1.73----
Free Cashflow-100.0%-120,729,00092,606,00069,259,00048,391,00022,602,0002,597,000-29,484,000-53,271,000-75,214,000-82,704,000-82,731,000-77,107,000-65,933,000-51,924,000-48,489,000-46,983,000----
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42017Q4
Assets0.4%78778364647641737334629927626927228128722123213814715853.0059.00
  Current Assets-22.8%45659145939535231028625624023324625826419821713114115249.0058.00
    Cash Equivalents-49.6%14128115712810066.0091.0093.0086.0058.0052.0021521812314039.0042.0013840.0052.00
  Inventory10.6%92.0083.0075.0069.0060.0053.0043.0039.0036.0034.0030.0029.0023.0016.0012.009.008.007.005.003.00
  Net PPE10.6%60.0054.0048.0039.0032.0028.0024.0023.0021.0020.0016.0013.0013.0013.005.004.003.003.003.001.00
  Goodwill0%40.0040.00------------------
Liabilities-20.2%17021313512011210510479.0068.0065.0046.0044.0042.0043.0039.0030.0027.0028.0023.005.00
  Current Liabilities-43.5%80.0014263.0054.0066.0051.0052.0040.0036.0033.0026.0021.0018.0019.0024.0019.0015.0015.009.005.00
    LT Debt, Current-------6.00-------------
Shareholder's Equity8.1%617571511356305268242220208204226237245178193108119129--
  Retained Earnings1248.4%31.002.00-36.81-177-212-238-252-265-267-267-243-227-214-196-177-163-150-139-126-85.76
  Additional Paid-In Capital3.1%5865695495355195074954864764714694654603743712712702694.002.00
Shares Outstanding0.6%37.0036.0036.0036.0036.0036.00--35,03034,797--32.0032.0024.0022.0019.009.002.002.00
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Cashflow From Operations7.3%16115011886.0061.0034.0015.00-18.19-43.95-64.30-71.18-71.35-65.53-57.88-48.11-45.35-44.63-44.50-41.46-42.20-43.53
  Share Based Compensation11.8%57.0051.0045.0040.0036.0032.0027.0022.0018.0014.0010.008.007.005.004.003.002.001.001.001.001.00
Cashflow From Investing-313.7%-118-28.55-62.15-49.98-49.48-28.0826.00-104-87.20-84.71-10763.0058.00-54.80-59.54-77.18-85.13-2.09-0.171.002.00
Cashflow From Financing-102.6%-2.4594.0013.004.006.003.00-2.45-1.78-2.8883.0090.0018518499.0020813113114330.0014.0021.00

SWAV Income Statement

2023-06-30
Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) - USD ($)
$ in Thousands
3 Months Ended6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Revenue:    
Product revenue$ 180,165$ 120,746$ 341,231$ 214,377
Cost of revenue:    
Cost of product revenue24,49316,73045,55929,620
Gross profit155,672104,016295,672184,757
Operating expenses:    
Research and development36,82920,76063,80037,779
Sales and marketing56,73840,515110,74976,476
General and administrative29,73113,16548,93525,554
Total operating expenses123,29874,440223,484139,809
Income from operations32,37429,57672,18844,948
Loss from equity method investment(146)(1,464)(969)(1,511)
Interest expense(810)(304)(1,446)(601)
Other income (expense), net1,586(1,473)3,968(1,783)
Net income before taxes33,00426,33573,74141,053
Income tax expense4,1427745,754971
Net income28,86225,56167,98740,082
Other comprehensive income (loss):    
Unrealized gain (loss) on available-for-sale securities(24)(320)481(1,135)
Adjustment for net gain realized and included in other income0050
Total comprehensive income$ 28,838$ 25,241$ 68,463$ 38,947
Net income per share    
Basic (USD per share)$ 0.79$ 0.71$ 1.86$ 1.12
Diluted (USD per share)$ 0.76$ 0.68$ 1.78$ 1.06
Denominator:    
Basic (in shares)36,663,32735,825,94736,545,94835,707,301
Diluted (in shares)38,226,15337,690,09438,139,94837,690,320
Type of Revenue [Extensible List]Product [Member]Product [Member]Product [Member]Product [Member]
Type of Cost, Good Or Service [Extensible List]Product [Member]Product [Member]Product [Member]Product [Member]

SWAV Balance Sheet

2023-06-30
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Jun. 30, 2023
Dec. 31, 2022
CURRENT ASSETS:  
Cash and cash equivalents$ 141,458$ 156,586[1]
Short-term investments117,131147,907[1]
Accounts receivable, net96,56271,366[1]
Inventory92,09375,112[1]
Prepaid expenses and other current assets9,1188,292[1]
Total current assets456,362459,263[1]
Operating lease right-of-use assets31,11732,365[1]
Property and equipment, net59,80348,152[1]
Equity method investment2,5433,512[1]
Intangible assets, net94,6920
Goodwill39,7890
Deferred tax assets94,69997,568
Other assets7,5995,229[1]
TOTAL ASSETS786,604646,089[1]
CURRENT LIABILITIES:  
Accounts payable12,8696,721[1]
Accrued liabilities65,76955,375[1]
Lease liability, current portion1,5821,278[1]
Total current liabilities80,22063,374[1]
Lease liability, noncurrent portion33,20534,928[1]
Debt, noncurrent portion24,26624,198[1]
Related party contract liability, noncurrent portion12,27312,273[1]
Deferred tax liabilities10,4210
Other liabilities9,3070
TOTAL LIABILITIES169,692134,773[1]
STOCKHOLDERS’ EQUITY:  
Preferred stock00[1]
Common stock3736[1]
Additional paid-in capital586,092548,960[1]
Accumulated other comprehensive loss(391)(867)[1]
Retained earnings (accumulated deficit)31,174(36,813)[1]
TOTAL STOCKHOLDERS’ EQUITY616,912511,316[1]
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY$ 786,604$ 646,089[1]
[1]The condensed consolidated balance sheet as of December 31, 2022 is derived from the audited consolidated financial statements as of that date.
Douglas E. Godshall
660
ShockWave Medical, Inc., a medical device company, engages in developing and commercializing intravascular lithotripsy technology for the treatment of calcified plaque in patients with peripheral vascular, coronary vascular, and heart valve diseases worldwide. The company offers M5 catheters for treating above-the-knee peripheral artery disease (PAD); C2 catheters for treating coronary artery disease; and S4 catheters for treating below-the-knee PAD. It serves interventional cardiologists, vascular surgeons, and interventional radiologists through sales representatives and sales managers, and distributors. The company was incorporated in 2009 and is headquartered in Santa Clara, California.